Skip navi

News

Learn what's new with KOLON Pharma.

Foster® has approved for COPD!

Foster® has approved for COPD!

"Foster is a fixed combination of beclomethasone dipropionate (corticosteroid) and formoterol fumarate (a long-acting β2-agonist with rapid onset of effect) to be taken by inhalation. In 2006 the drug was approved for the maintenance therapy of asthma; after its first launch in Germany on October 2006, it is now sold in over 35 countries worldwide, including Russia and China. Further launches are planned throughout 2014. Foster is also available as a DPI ( Dry Powder Inhaler, in NEXThaler device) in the asthma indication. Foster’s key feature is its extra-fine formulation, which guarantees the uniform distribution and high drug deposition throughout the entire bronchial tree, including the small airways. In 2013, Foster pMDI obtained the approval of the MART (Maintenance And Reliever Therapy) posology and the approval of COPD indication is another important achievement for this product. With the new approval in COPD, Foster pMDI is achieving a broader therapeutic indication in patients with obstructive respiratory disorders and it is expected to become one of the recommended inhalation options in this steadily increasing population of patients."  Foster®, representative ethical drug of Kolonpharma, has approaved for COPD in 1st Sep 2015. Foster® has gained permission to be prescribed if FEV1 indicates lower than 60%. The guideline of KATRD(The Korean Academy of Tuberculosis and Respiratory Diseases) for COPD treatment also recommends ICS/LABA combination drug  in cases that FEV1 goes to lower than 60% of normal condition or if there were more than 2 cases of acute exacerbation in the past a year. Foster® is a fixed combination of beclomethasone dipropionate (corticosteroid) and formoterol fumarate (a long-acting β2-agonist with rapid onset of effect) to be taken by inhalation.

  • 2015.12.11
  • Hit. 68
Bicogreen S Tab., 'To You Who Never Changes': Announcement of the Selected Work of the Public Copy Contribution for the New Package

Bicogreen S Tab., 'To You Who Never Changes': Announcement of the Selected Work of the Public Copy Contribution for the New Package

With the successful completion of 'The Public Copy Contribution for the New Package of Bicogreen S Tab.' by KOLON Pharma from last June 8th to June 26th for 19 days holding about 7000 participants, the selected work was announced.      In the public copy contribution for the new package through Bicogreen S Facebook, 'To You Who Never Changes' by Seung-won Na* won the grand prize through the final screening. 'Who Told You No News are Good News?' won the highest work award, and the outstanding work was 'Good Night while Eating, and Good Morning When Digested.' According to the panel of judges they "selected the works based on the applicability of whether the copy expressed the ambiguous words which the real sufferers from constipation can sympathize with, and the attempt at marketing with Facebook and the public contribution as the strategy of marketing working in both directions with the consumers was new and effective." The prize money of 2 million KRW will be given to the grand prize winner of the public contribution, 'To You Who Never Changes,' and 1 million KRW to the highest work award and 500,000 KRW for the outstanding award will be delivered. Also, the set gifts will be given to the winners of the 50 participants' awards and the selected 3 copies will be used as the package copies of Bicogreen S Tab. and again in the theater advertisement during July and August along with the bus advertisement in the regions of Seoul · Gyeonggi. They stated that from now on the consistent communication with the consumers through Bicogreen S Tab. Facebook (www.facebook.com/bicogreens) will be continued such as diverse public contribution and events where the consumers participate. Bicogreen S Tab. promotes the peristalsis of the colon from the outset by regulating the breaking down speed in the intestines rapidly, and manifests an effect in 7~8 hours of internal application. It is developed as the smallest tablet among the domestic constipation medicines for handy carrying.

  • 2015.07.03
  • Hit. 27
Bicogreen S Tab. of KOLON Pharma, Holding 'the Public Contribution for the Main Copy' of the New Package

Bicogreen S Tab. of KOLON Pharma, Holding 'the Public Contribution for the Main Copy' of the New Package

The advertising planner of 'Bicogreen S Tab.', a remedy for constipation, which newly made a renewal of the package last month, reported that it will promote the public contribution for the copy of the package on the 8th.         This public contribution is planned to promote the communication with the consumers through the novel story in a line from the consumers that the general public as well as the sufferers from 'constipation' can sympathize with by the motif of an SNS short poem which is recently popular among the young generation.   The advertising planner of Bicogreen S Tab. told that “This public contribution is supported · superintended directly by the advertising planner as a marketing for sympathizing with the consumers, and used for the product package of Bicogreen S Tab.” The famous author of the webtoon, 'A Gale Planning,' Lee Hyun-min participated in the production of the poster for the public contribution.   Anybody sick from constipation or healthy with the intestines who has a copy idea suitable for the subject can easily participate in the public contribution of the copy for Bicogreen S Tab. The application for the public contribution will be accepted by the replying message after reading the 'Blue Jokes' webtoon on the Bicogreen S Tab. Facebook page (www.facebook.com/bicogreens) from June 8th (Mon) to the 25th (Thu). This public contribution will select the copy of sympathy, the prize money of 2 million KRW will be given to one grand prize winner, and 1 million KRW to the highest work award of one person and 500,000 KRW to the outstanding award of one person will be delivered. Also the successful works will be given a fixed gift. Again the selected 3 copies will be used as the package copy of Bicogreen S Tab., and in the theater advertisement during July and August along with the bus advertisement in the regions of Seoul · Gyeonggi. Other than the public contribution, the Bicogreen S Tab. Facebook will open diverse activities for the communication with the customers. This Bicogreen S Tab. campaign is an attempt at new marketing to constantly listen to the voice of the customers and to activate further the communication with the customers through Facebook for the construction of the consumer-centered trend and brand that reflect the voice of the consumers.   Bicogreen S Tab. exhibits excellent efficacy by adding calcium sennoside, a natural component, which helps the colon movement to the components of bisacodyl and docusate sodium, and regulates the breaking down speed in the intestines swiftly for the promotion of the colon movements from the outset. According to the symptoms of constipation, the intake dosage can be adjusted from 1~3 tablets, and the effect is manifested in 7~8 hours of the internal application. Also, it is developed as the smallest size tablet among the domestic constipation medicines, and handy carrying during outings is possible.

  • 2015.06.08
  • Hit. 13
<< <1> >>
top